表皮生长因子受体突变或间变性淋巴瘤激酶阳性非小细胞肺癌伴脑转移患者中，靶向治疗作为全脑放疗的替代选择。
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.
机构信息
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Radiation Oncology, Brigham and Women's Hospital & Dana-Farber Cancer Institute, Boston, Massachusetts.
出版信息
JAMA Oncol. 2017 Sep 1;3(9):1274-1275. doi: 10.1001/jamaoncol.2017.1047.
CLINICAL QUESTION
Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted therapies are available?
CLINICAL APPLICATION
Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole-brain radiotherapy can be safely postponed, diminishing toxic effects that could impair quality of life.
临床问题
当有高度有效的靶向治疗时，是否需要对非小细胞肺癌的多发脑转移进行 upfront 全脑放疗？
临床应用
目前，脑转移的 EGFR 突变或 ALK 阳性非小细胞肺癌患者有延长生存的可能。通过使用高度有效的靶向治疗，全脑放疗可以安全地推迟，减少可能损害生活质量的毒性作用。
Zotero 插件